Drugs giant AstraZeneca has filed a lawsuit against US regulators to overturn last week's denial of petitions with regard to generic versions of its SEROQUEL and SEROQUEL XR tablets.
The tablets, also know as 'quetiapine fumarate', are an antispsychotic drug used in the treatment of schizophrenia, bipolar disorder and depression.
On March 7th, Astra filed a 'citizens petition' to raise issues regarding labelling requirements for generic copies of "innovative medicines" as well as data exclusivity rights. This was denied by the Food and Drug Administration (FDA).
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company is attempting to delay the realise onto the market of the generics.
"AstraZeneca seeks an injunction barring the FDA from granting final marketing approval of generic quetiapine until December 2nd 2012 when regulatory exclusivity expires on important clinical trial data, or, alternatively, at least until a federal court has a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications," the firm said on Tuesday morning.
"AstraZeneca will vigorously defend its legal rights."
BC
-
Millions at risk of 'unnecessary' tax bill – how to shield your savingsMillions of Brits could be taxed on their savings interest this year as their savings interest exceeds the personal savings allowance. Are you at risk?
-
Savers will have to wait as long as 48 years to build a £1m cash ISA pot if allowance is cutChancellor Rachel Reeves is rumoured to be planning a cut to the cash ISA allowance in the Autumn Budget, making it harder for savers to build wealth. Will you still be able to build a £1 million cash ISA pot?
